American Century Companies Inc. Sells 2,951 Shares of Organon & Co. $OGN

American Century Companies Inc. reduced its position in Organon & Co. (NYSE:OGN) by 6.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,997 shares of the company’s stock after selling 2,951 shares during the quarter. American Century Companies Inc.’s holdings in Organon & Co. were worth $596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Organon & Co. during the first quarter worth $60,000. PARK CIRCLE Co boosted its position in shares of Organon & Co. by 640.7% during the first quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock worth $60,000 after acquiring an additional 3,460 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Organon & Co. by 186.9% during the first quarter. GAMMA Investing LLC now owns 4,611 shares of the company’s stock worth $69,000 after acquiring an additional 3,004 shares during the last quarter. Cary Street Partners Financial LLC bought a new position in shares of Organon & Co. during the fourth quarter worth $111,000. Finally, SBI Securities Co. Ltd. boosted its position in shares of Organon & Co. by 17.6% during the first quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company’s stock worth $114,000 after acquiring an additional 1,145 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Piper Sandler dropped their target price on shares of Organon & Co. from $24.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, May 15th. BNP Paribas upgraded shares of Organon & Co. to a “strong-buy” rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Trading Up 7.1%

Shares of OGN opened at $10.37 on Friday. Organon & Co. has a twelve month low of $8.01 and a twelve month high of $21.25. The company has a market cap of $2.69 billion, a P/E ratio of 3.85, a P/E/G ratio of 0.88 and a beta of 0.60. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The company’s fifty day simple moving average is $9.59 and its 200-day simple moving average is $11.06.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm’s revenue was down .8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Friday, August 15th will be paid a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Organon & Co.’s dividend payout ratio (DPR) is currently 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.